Wegovy Cost UK: NHS vs Private Prescription Pricing Guide

Wegovy (semaglutide 2.4 mg) has emerged as a significant advancement in chronic weight management, but understanding the cost implications is essential for UK patients considering this treatment. Whether accessed through the NHS or private prescription, Wegovy pricing varies considerably based on supply route, prescriber type, and treatment duration. This article examines the factors influencing Wegovy costs in the UK, compares NHS and private prescription routes, explores alternative weight management options, and provides practical guidance on accessing this MHRA-licensed medication safely and affordably within the UK healthcare system.

What Is Wegovy and How Does It Work?

Wegovy (semaglutide 2.4 mg) is a once-weekly subcutaneous injection licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for chronic weight management in adults with obesity or overweight with weight-related comorbidities.^[3][23] It is also licensed for use in adolescents aged 12 years and above in specialist settings. It belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for type 2 diabetes management but now widely recognised for their significant weight loss effects.

The mechanism of action centres on mimicking the naturally occurring hormone GLP-1, which is released from the gut after eating. Semaglutide binds to GLP-1 receptors in multiple tissues, including the brain, pancreas, and gastrointestinal tract.^[9][11] In the hypothalamus, it reduces appetite and increases feelings of satiety, leading to decreased caloric intake. It also transiently slows gastric emptying, prolonging the sensation of fullness after meals. In the pancreas, it enhances glucose-dependent insulin secretion and suppresses glucagon release, improving glycaemic control.

Clinical trials have demonstrated that Wegovy, when combined with lifestyle interventions including reduced-calorie diet and increased physical activity, can produce average weight loss of 10–15% of initial body weight over 68 weeks. The medication is administered via a pre-filled pen injector, with doses gradually titrated over 16 weeks (0.25→0.5→1.0→1.7→2.4 mg at 4-week intervals, with slower escalation if not tolerated) to minimise gastrointestinal side effects. Common adverse effects include nausea, vomiting, diarrhoea, constipation, and abdominal pain, which typically diminish as the body adjusts to treatment.^[3][23]

Wegovy is not suitable for everyone. Contraindications include pregnancy, hypersensitivity to semaglutide or any excipients, and it should not be used during breastfeeding. Caution is advised in patients with a history of pancreatitis, gallbladder disease, or diabetic retinopathy. Patients should seek urgent medical attention for severe, persistent abdominal pain with or without vomiting (potential pancreatitis). Patients should be counselled about the importance of adherence to lifestyle modifications, as the medication is most effective as part of a comprehensive weight management programme.

If you experience any side effects, talk to your healthcare professional. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Factors That Affect Wegovy Pricing

The cost of Wegovy in the UK varies considerably depending on several key factors, making it essential for patients to understand the pricing landscape before commencing treatment. Supply route, dosage requirements, treatment duration, and prescriber type all significantly influence the final price.

When obtained privately, Wegovy typically costs between £200 and £300 per month for the maintenance dose (2.4 mg weekly), though these prices are indicative and subject to change. The initial titration phase may cost less, as lower starter doses are used. Some private clinics bundle consultation fees, follow-up appointments, and medication costs into package deals ranging from £500 to £1,000 for the first three months. Patients should clarify exactly what is included in quoted prices, as hidden costs for consultations, blood tests, or delivery can substantially increase the overall expenditure.

Pharmacy choice also impacts pricing. Online pharmacies and telehealth services often offer competitive rates compared to traditional high-street pharmacies, though patients must ensure they are using General Pharmaceutical Council (GPhC)-registered providers and that prescribers comply with General Medical Council (GMC) remote prescribing standards. Some services offer subscription models with monthly direct debits, whilst others require upfront payment for multiple months, occasionally with modest discounts for bulk purchases.

Supply chain issues have periodically affected Wegovy availability since its UK launch, with manufacturer Novo Nordisk implementing controlled distribution to manage demand, as noted in Department of Health and Social Care (DHSC) supply disruption alerts. During shortage periods, waiting lists have developed and availability may be limited. Geographic location within the UK can also influence costs, with London-based private clinics typically charging premium rates compared to providers in other regions.

Insurance coverage represents another variable. Most standard private medical insurance policies in the UK do not cover weight management medications, though some employers offer enhanced health plans that may provide partial reimbursement. Patients should check their policy documents carefully and obtain pre-authorisation where required.

Alternatives to Wegovy for Weight Management

For patients unable to access or afford Wegovy, several evidence-based alternatives exist for weight management, each with distinct mechanisms, efficacy profiles, and cost implications. Understanding these options enables informed decision-making in consultation with healthcare professionals.

Saxenda (liraglutide 3.0 mg) is another GLP-1 receptor agonist licensed for weight management, administered as a daily subcutaneous injection.^[3][23] Whilst clinical trials show slightly lower average weight loss compared to Wegovy (approximately 5–8% of initial body weight), it remains an effective option. Private costs are similar to Wegovy, ranging from £150 to £250 monthly. The daily injection requirement may be less convenient for some patients, though others prefer the flexibility of daily dosing.

Orlistat is widely available on NHS prescription in primary care and over-the-counter (as alli at 60 mg strength; prescription Xenical is 120 mg). This lipase inhibitor reduces dietary fat absorption by approximately 30%, leading to average weight loss of 3–5% when combined with a reduced-calorie, lower-fat diet. Common side effects include oily stools, faecal urgency, and flatulence, particularly when dietary fat intake is not adequately restricted. Orlistat costs approximately £20–40 monthly for the 120 mg prescription strength, making it significantly more affordable than GLP-1 agonists.

Mysimba (naltrexone/bupropion) is a combination medication licensed for weight management in the UK. It works by affecting brain pathways involved in hunger and reward. Average weight loss is approximately 4–8% of initial body weight. Side effects include nausea, constipation, headache, and insomnia. Private costs range from £100–£180 monthly, and NHS availability is limited.

Mounjaro (tirzepatide), a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, has received MHRA approval for type 2 diabetes and is under evaluation for weight management indication. Early evidence suggests superior weight loss compared to semaglutide, though UK availability for obesity treatment remains limited pending regulatory decisions.

Bariatric surgery (such as gastric bypass, sleeve gastrectomy) offers the most significant and sustained weight loss for eligible patients. NHS referral criteria typically include BMI ≥40 kg/m² or BMI ≥35 kg/m² with weight-related conditions, plus previous unsuccessful weight management attempts. Waiting times vary regionally.

Behavioural and lifestyle interventions remain the cornerstone of weight management. NHS-funded programmes such as the NHS Digital Weight Management Programme offer structured support at no cost to eligible patients. Commercial programmes like Weight Watchers (WW) or Slimming World typically cost £5–20 weekly. Whilst medication can enhance outcomes, sustainable weight loss fundamentally requires dietary modification, increased physical activity, and behavioural change strategies.

Wegovy Cost in the UK: NHS vs Private Prescriptions

The availability and cost of Wegovy through NHS versus private routes differs substantially, reflecting resource constraints and clinical prioritisation within the publicly funded healthcare system.

NHS availability of Wegovy is currently limited following NICE guidance published in March 2023 (TA875). NICE recommended semaglutide 2.4 mg for weight management in adults with at least one weight-related comorbidity and either a BMI ≥35 kg/m² (or ≥32.5 kg/m² for people from some Asian, Black and other minority ethnic groups) or BMI ≥30 kg/m² (or ≥27.5 kg/m² for people from some ethnic groups) with specific conditions. Implementation is restricted to specialist weight management services, with treatment limited to a maximum of 2 years.^[7][8] Access varies regionally, with Integrated Care Boards maintaining eligibility criteria and waiting lists. Where available through the NHS, patients pay only the standard prescription charge of £9.90 per item in England (prescriptions are free in Scotland, Wales, and Northern Ireland), representing exceptional value.

The NHS pathway typically requires:

• Documented evidence of previous weight management attempts

• Assessment by specialist obesity services

• Commitment to structured lifestyle intervention programme

• Regular monitoring and review appointments

• Discontinuation if treatment response criteria are not met as per local specialist protocols and the product licence

Private prescription routes offer significantly greater accessibility but at substantial cost. Patients can access Wegovy through private GPs, specialist weight management clinics, or regulated online prescribing services. Total monthly costs typically include:

• Initial consultation: £50–200

• Medication: £200–300 per month at maintenance dose

• Follow-up consultations: £30–100 every 1–3 months

• Blood tests (if required): £50–150

Over a typical 12-month treatment course, private patients should budget £2,500–4,000 for comprehensive care. Some providers offer payment plans to spread costs, though interest may apply.

Patient safety considerations apply regardless of funding route. Both NHS and private prescribers should conduct baseline assessments including weight, BMI, blood pressure, and relevant blood tests (HbA1c, lipids, liver function) as clinically appropriate. Patients should be counselled about potential side effects, the importance of gradual dose escalation, and when to seek medical attention—particularly for severe abdominal pain (potential pancreatitis), persistent vomiting leading to dehydration, or signs of gallbladder disease. Women of childbearing potential should use effective contraception during treatment and discontinue Wegovy at least 2 months before a planned pregnancy. For patients with type 2 diabetes, medication adjustments may be needed to prevent hypoglycaemia, particularly if taking insulin or sulfonylureas. Regular monitoring ensures treatment remains appropriate and effective, with discontinuation considered if weight loss targets are not achieved or side effects become intolerable.

Frequently Asked Questions